Clinical trialNCT06337318RecruitingPhase 3Interventional

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

SponsorNational Cancer Institute (NCI)Enrollment600Classic Follicular LymphomaFollicular Lymphoma With Unusual Cytological Features

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Nilanjan Ghosh
SWOG Cancer Research Network
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

275 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
Aditi Saha
Recruiting
Mayo Clinic Hospital in Arizona
Phoenix, Arizona, United States
Jose C. Villasboas
Recruiting
Banner University Medical Center - Tucson
Tucson, Arizona, United States
Krishna Rekha Moturi
Recruiting
University of Arizona Cancer Center-North Campus
Tucson, Arizona, United States
Krishna Rekha Moturi
Recruiting
Highlands Oncology Group - Fayetteville
Fayetteville, Arkansas, United States
Joseph T. Beck
Recruiting
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Mamatha Gaddam
Recruiting
Highlands Oncology Group - Rogers
Rogers, Arkansas, United States
Joseph T. Beck
Recruiting
Highlands Oncology Group
Springdale, Arkansas, United States
Joseph T. Beck
Recruiting
Tower Cancer Research Foundation
Beverly Hills, California, United States
Akil A. Merchant
Recruiting
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Tycel J. Phillips
Recruiting
City of Hope at Irvine Lennar
Irvine, California, United States
Tycel J. Phillips
Recruiting
Uci Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, United States
Elizabeth A. Brem
Recruiting
City of Hope Antelope Valley
Lancaster, California, United States
Tycel J. Phillips
Recruiting
City of Hope at Long Beach Elm
Long Beach, California, United States
Tycel J. Phillips
Recruiting
Tibor Rubin Va Medical Center
Long Beach, California, United States
Helen Ma
Recruiting
Cedars-Sinai Medical Center
Los Angeles, California, United States
Akil A. Merchant
Recruiting
Uc Irvine Health/chao Family Comprehensive Cancer Center
Orange, California, United States
Elizabeth A. Brem
Recruiting
City of Hope South Pasadena
South Pasadena, California, United States
Tycel J. Phillips
Recruiting
Torrance Memorial Physician Network - Cancer Care
Torrance, California, United States
Akil A. Merchant
Recruiting
City of Hope Upland
Upland, California, United States
Tycel J. Phillips
Recruiting
Uchealth University of Colorado Hospital
Aurora, Colorado, United States
Manali K. Kamdar
Recruiting
Cancer Care and Hematology-Fort Collins
Fort Collins, Colorado, United States
Manali K. Kamdar
Recruiting
Poudre Valley Hospital
Fort Collins, Colorado, United States
Manali K. Kamdar
Recruiting
Uchealth Greeley Hospital
Greeley, Colorado, United States
Manali K. Kamdar
Recruiting
Medical Center of the Rockies
Loveland, Colorado, United States
Manali K. Kamdar
Recruiting
Helen F Graham Cancer Center
Newark, Delaware, United States
Gregory A. Masters
Recruiting
Medical Oncology Hematology Consultants Pa
Newark, Delaware, United States
Gregory A. Masters
Recruiting
Medstar Georgetown University Hospital
Washington D.C., District of Columbia, United States
Joseph L. Roswarski
Recruiting
Sibley Memorial Hospital
Washington D.C., District of Columbia, United States
Nina D. Wagner-Johnston
Recruiting
Um Sylvester Comprehensive Cancer Center at Aventura
Aventura, Florida, United States
Michele Stanchina
Recruiting
Um Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, United States
Michele Stanchina
Recruiting
Um Sylvester Comprehensive Cancer Center at Coral Springs
Coral Springs, Florida, United States
Michele Stanchina
Recruiting
Um Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, United States
Michele Stanchina
Recruiting
Um Sylvester Comprehensive Cancer Center at Doral
Doral, Florida, United States
Michele Stanchina
Recruiting
Um Sylvester Comprehensive Cancer Center at Hollywood
Hollywood, Florida, United States
Michele Stanchina
Recruiting
Mayo Clinic in Florida
Jacksonville, Florida, United States
Jose C. Villasboas
Recruiting
Um Sylvester Comprehensive Cancer Center at Kendall
Miami, Florida, United States
Michele Stanchina
Recruiting
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, United States
Michele Stanchina
Recruiting
Mount Sinai Medical Center
Miami Beach, Florida, United States
Jacqueline C. Barrientos
Recruiting
University of Miami Sylvester Comprehensive Cancer Center at Sole Mia
North Miami, Florida, United States
Michele Stanchina
Recruiting

235 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Mosunetuzumab →Rituximab →Rituximab and Hyaluronidase Human

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 23 Oct 2024
Primary completion: 31 Mar 2032
Completion: 31 Mar 2032
Last update posted: 21 Aug 2026
Registered enrollment: 600
Registry id: NCT06337318

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.